BACKGROUND: The clinical manifestations of @entity66 include @entity299 (including @entity583 [ @entity583 ]) and @entity66 (including @entity64 [ @entity64 ]). Although costs generated by the clinical manifestations of @entity66 represent an important economic burden for any healthcare system, very few economic comparative data are available. OBJECTIVE: To: (i) assess management costs of the different practice patterns for acute and chronic phases for @entity583 , @entity64 and @entity3657 ( @entity3657 ) in eight European countries; and (ii) to simulate the cost of managing a @entity1 with an @entity66 for 2 years in Europe. STUDY PERSPECTIVE: Healthcare system. METHODS: Firstly, the medical costs of managing @entity583 and @entity64 were analysed during the acute phase and subsequent 6-month periods over a total of 2 years. In each case, a decision tree was designed to indicate resource use. Assumptions concerning @entity1 management and resource use were based on currently available local and international literature, official national statistics and local expert opinions (Delphi panel). Costs were assessed using diagnosis-related groups (Austria, Italy, Portugal and Sweden), or hospital databases and national tariffs (Belgium, France, Spain and Switzerland). Secondly, these costs were correlated to data from a large randomised clinical trial to estimate the overall cost per @entity1 with @entity66 over a 2-year period. RESULTS: For @entity583 , there was a 2-fold difference in costs between the eight countries (euro9512-18 293), with 47-76% of costs devoted to acute management, 14-48% to follow-up management during the first year, and 4-17% to follow-up during the second year. For @entity64 , there was a 10-fold difference (euro5607-56 370), with 18-75% devoted to follow-up for the years 1995-1997. CONCLUSIONS: There are differences in the overall costs and cost breakdown in the clinical management patterns of @entity583 and @entity64 in Europe. These differences seem to arise as a result of local treatment pattern specificities as well as the availability of specific and well-adapted structures for @entity1 ' rehabilitation. Further studies are necessary to fully explain these differences. The assessment of the total medical costs of managing an atherothrombotic @entity1 over a 2-year period ( @entity583 , @entity64 , established @entity3657 ) has to take into account the risk of ischaemic events in different @entity455 ( @entity583 , @entity64 or major leg ischaemia).

The comparative medical costs of XXXX in European countries.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity64 :: ('MESH:D020521', 'Disease') :: ['IS', 'ischaemic stroke'] @entity455 :: ('MESH:D014652', 'Disease') :: ['vascular areas'] @entity66 :: ('MESH:D004194', 'Disease') :: ['cerebrovascular disease', 'atherothrombotic disease'] @entity3657 :: ('MESH:D058729', 'Disease') :: ['PAD', 'peripheral arterial disease'] @entity299 :: ('MESH:D006331', 'Disease') :: ['ischaemic heart disease'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction', 'MI']
@entity66 :: (MESH:D004194,Disease) :: ['atherothrombotic disease']
